CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06115499
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:41.537886+00:00
Published At: 2026-01-07T00:00:00+00:00
Record Updated At: 2026-01-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Acinar Cell Carcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma", "Pancreatic Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Squamous Cell Carcinoma", "Stage IV Pancreatic Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-07"
protocolSection.identificationModule.nctId: "NCT06115499"
protocolSection.identificationModule.officialTitle: "Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.